- Design
- Systematic review and meta-analysis of matched observational cohorts
- Population
- About 1,300 adults with IBD, with versus without prior SARS-CoV-2 (Italy and USA)
- Primary outcome
- IBD course after COVID-19 and effect of biologic interruption
- Effect
- COVID worsening IBD OR 1.06 (0.76-1.49); flares ~52% vs ~18% when biologics delayed or stopped
A meta-analysis of matched cohorts (about 1,300 patients in Italy and the USA) examined whether SARS-CoV-2 infection worsens inflammatory bowel disease, and what happens when biologics are interrupted around it.
Prior COVID-19 did not worsen the IBD course (odds ratio 1.06), nor change ulcerative colitis extent or Crohn's behaviour. What mattered was treatment continuity: infection was strongly associated with biologic delay or discontinuation (odds ratio 10.44), and flares were far more common when biologics were stopped (about 52% vs 18%, a 34-percentage-point difference).
The actionable message is to resist reflexively pausing biologics when a patient with IBD gets COVID. In those without high-risk features for severe COVID-19, maintaining biologic therapy prevents flares, and the infection itself does not appear to drive the disease. The evidence is a small set of observational cohorts, so individualise in genuinely high-risk patients.
- Prior COVID-19 did not worsen the IBD course (odds ratio 1.06).
- Flares were far more common when biologics were delayed or stopped (about 52% vs 18%).
- Infection was strongly linked to biologic interruption (odds ratio 10.44).
- Do not reflexively pause biologics when an IBD patient gets COVID.
- Individualise in patients with genuine high-risk features for severe COVID-19.
Why it matters
It counters an instinct to hold immunosuppression during infection, which here does more harm than the infection itself.
Don't overread it
Few small observational cohorts; the flare association with stopping biologics may be confounded by the reasons therapy was paused.
The statistics, in plain English
An odds ratio near 1.0 for COVID worsening IBD means no effect; the large flare difference when biologics stopped is observational, so partly reflects why therapy was interrupted, but the direction is consistent.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for gastroenterology & hepatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free